tradingkey.logo
tradingkey.logo

Charles River Laboratories International Inc

CRL
220.910USD
+5.400+2.51%
終値 01/09, 16:00ET15分遅れの株価
10.87B時価総額
損失額直近12ヶ月PER

Charles River Laboratories International Inc

220.910
+5.400+2.51%

詳細情報 Charles River Laboratories International Inc 企業名

Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.

Charles River Laboratories International Incの企業情報

企業コードCRL
会社名Charles River Laboratories International Inc
上場日Jun 23, 2000
最高経営責任者「CEO」Foster (James C)
従業員数18600
証券種類Ordinary Share
決算期末Jun 23
本社所在地251 Ballardvale St
都市WILMINGTON
証券取引所NASDAQ OMX NASDAQ Basic NYSE
United States of America
郵便番号01887
電話番号17812226000
ウェブサイトhttps://www.criver.com/
企業コードCRL
上場日Jun 23, 2000
最高経営責任者「CEO」Foster (James C)

Charles River Laboratories International Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. James C. Foster
Mr. James C. Foster
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
267.96K
+17253.00%
Ms. Birgit Girshick
Ms. Birgit Girshick
Chief Operating Officer, Corporate Executive Vice President
Chief Operating Officer, Corporate Executive Vice President
57.72K
+11316.00%
Ms. Victoria L. (Vicky) Creamer
Ms. Victoria L. (Vicky) Creamer
Corporate Executive Vice President, Chief People Officer
Corporate Executive Vice President, Chief People Officer
17.89K
+5856.00%
Ms. Shannon M. Parisotto
Ms. Shannon M. Parisotto
Corporate Executive Vice President - Discovery and Safety Assessment Management
Corporate Executive Vice President - Discovery and Safety Assessment Management
12.88K
+5285.00%
Mr. Joseph W. LaPlume
Mr. Joseph W. LaPlume
Corporate Executive Vice President - Corporate Development and Strategy
Corporate Executive Vice President - Corporate Development and Strategy
12.48K
-1200.00%
Ms. Virginia M. (Gina) Wilson, CPA
Ms. Virginia M. (Gina) Wilson, CPA
Independent Director
Independent Director
4.91K
+946.00%
Dr. Nancy C. Andrews, M.D., Ph.D.
Dr. Nancy C. Andrews, M.D., Ph.D.
Independent Director
Independent Director
3.96K
+946.00%
Ms. Reshema Kemps-Polanco
Ms. Reshema Kemps-Polanco
Independent Director
Independent Director
2.59K
+1576.00%
Dr. Craig B. Thompson, M.D.
Dr. Craig B. Thompson, M.D.
Independent Director
Independent Director
2.41K
+946.00%
Mr. Paul W. Graves
Mr. Paul W. Graves
Independent Director
Independent Director
946.00
+946.00%
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. James C. Foster
Mr. James C. Foster
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
267.96K
+17253.00%
Ms. Birgit Girshick
Ms. Birgit Girshick
Chief Operating Officer, Corporate Executive Vice President
Chief Operating Officer, Corporate Executive Vice President
57.72K
+11316.00%
Ms. Victoria L. (Vicky) Creamer
Ms. Victoria L. (Vicky) Creamer
Corporate Executive Vice President, Chief People Officer
Corporate Executive Vice President, Chief People Officer
17.89K
+5856.00%
Ms. Shannon M. Parisotto
Ms. Shannon M. Parisotto
Corporate Executive Vice President - Discovery and Safety Assessment Management
Corporate Executive Vice President - Discovery and Safety Assessment Management
12.88K
+5285.00%
Mr. Joseph W. LaPlume
Mr. Joseph W. LaPlume
Corporate Executive Vice President - Corporate Development and Strategy
Corporate Executive Vice President - Corporate Development and Strategy
12.48K
-1200.00%
Ms. Virginia M. (Gina) Wilson, CPA
Ms. Virginia M. (Gina) Wilson, CPA
Independent Director
Independent Director
4.91K
+946.00%

収益内訳

通貨: USD更新時刻: Tue, Jan 6
通貨: USD更新時刻: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
事業別USD
会社名
収益
比率
DSA
600.68M
59.78%
RMS
213.47M
21.24%
Manufacturing
190.69M
18.98%
地域別USD
会社名
収益
比率
United States
537.61M
53.50%
Europe
277.69M
27.63%
Canada
116.81M
11.62%
Asia Pacific (Region)
51.66M
5.14%
Other
21.08M
2.10%
事業別
地域別
事業別USD
会社名
収益
比率
DSA
600.68M
59.78%
RMS
213.47M
21.24%
Manufacturing
190.69M
18.98%

株主

更新時刻: Sat, Dec 27
更新時刻: Sat, Dec 27
株主統計
種類
株主統計
株主統計
比率
The Vanguard Group, Inc.
11.84%
Wellington Management Company, LLP
6.48%
BlackRock Institutional Trust Company, N.A.
5.73%
Allspring Global Investments, LLC
4.43%
State Street Investment Management (US)
3.72%
他の
67.80%
株主統計
株主統計
比率
The Vanguard Group, Inc.
11.84%
Wellington Management Company, LLP
6.48%
BlackRock Institutional Trust Company, N.A.
5.73%
Allspring Global Investments, LLC
4.43%
State Street Investment Management (US)
3.72%
他の
67.80%
種類
株主統計
比率
Investment Advisor/Hedge Fund
45.17%
Investment Advisor
44.43%
Hedge Fund
7.70%
Research Firm
4.24%
Bank and Trust
3.01%
Pension Fund
1.52%
Individual Investor
1.06%
Sovereign Wealth Fund
1.04%
Insurance Company
0.08%

機関投資家保有株

更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
1375
52.90M
107.49%
-10.65M
2025Q3
1413
52.22M
129.54%
+64.86K
2025Q2
1411
52.12M
127.74%
-2.86M
2025Q1
1414
54.69M
123.53%
-5.98M
2024Q4
1410
54.25M
114.75%
+1.17M
2024Q3
1372
53.38M
114.53%
-33.66K
2024Q2
1378
53.46M
111.45%
+347.48K
2024Q1
1371
53.18M
111.09%
-4.05M
2023Q4
1405
52.96M
112.24%
-202.82K
2023Q3
1421
52.99M
111.08%
+631.82K
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
The Vanguard Group, Inc.
5.83M
11.84%
+27.29K
+0.47%
Sep 30, 2025
Wellington Management Company, LLP
3.19M
6.48%
-577.34K
-15.32%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.82M
5.73%
+69.84K
+2.54%
Sep 30, 2025
Allspring Global Investments, LLC
2.18M
4.43%
-113.19K
-4.94%
Sep 30, 2025
State Street Investment Management (US)
1.83M
3.72%
-27.63K
-1.49%
Sep 30, 2025
Ariel Investments, LLC
1.49M
3.03%
+74.75K
+5.28%
Sep 30, 2025
Harris Associates L.P.
1.47M
2.99%
+310.15K
+26.67%
Sep 30, 2025
Geode Capital Management, L.L.C.
1.27M
2.57%
+34.52K
+2.80%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
1.13M
2.3%
+120.21K
+11.89%
Sep 30, 2025
Invesco Capital Management LLC
1.10M
2.24%
+10.09K
+0.92%
Sep 30, 2025
詳細を見る

関連ETF

更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Invesco S&P 500 Equal Weight Health Care ETF
1.92%
Schwab Ariel Opportunities ETF
1.82%
iShares Health Innovation Active ETF
1.74%
First Trust NASDAQ Pharmaceuticals ETF
1.71%
ROBO Global Healthcare Technology & Innovation ETF
1.69%
VanEck Biotech ETF
1.44%
Franklin Genomic Advancements ETF
1.42%
WisdomTree US Value Fund
1.15%
Invesco S&P 500 High Beta ETF
1.14%
Pacer Lunt Large Cap Alternator ETF
0.97%
詳細を見る
Invesco S&P 500 Equal Weight Health Care ETF
比率1.92%
Schwab Ariel Opportunities ETF
比率1.82%
iShares Health Innovation Active ETF
比率1.74%
First Trust NASDAQ Pharmaceuticals ETF
比率1.71%
ROBO Global Healthcare Technology & Innovation ETF
比率1.69%
VanEck Biotech ETF
比率1.44%
Franklin Genomic Advancements ETF
比率1.42%
WisdomTree US Value Fund
比率1.15%
Invesco S&P 500 High Beta ETF
比率1.14%
Pacer Lunt Large Cap Alternator ETF
比率0.97%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
種類
比率
データなし
日付
種類
比率
データなし

よくある質問

Charles River Laboratories International Incの上位5名の株主は誰ですか?

Charles River Laboratories International Incの上位5名の株主は以下のとおりです。
The Vanguard Group, Inc.は5.83M株を保有しており、これは全体の11.84%に相当します。
Wellington Management Company, LLPは3.19M株を保有しており、これは全体の6.48%に相当します。
BlackRock Institutional Trust Company, N.A.は2.82M株を保有しており、これは全体の5.73%に相当します。
Allspring Global Investments, LLCは2.18M株を保有しており、これは全体の4.43%に相当します。
State Street Investment Management (US)は1.83M株を保有しており、これは全体の3.72%に相当します。

Charles River Laboratories International Incの株主タイプ上位3種は何ですか?

Charles River Laboratories International Incの株主タイプ上位3種は、
The Vanguard Group, Inc.
Wellington Management Company, LLP
BlackRock Institutional Trust Company, N.A.

Charles River Laboratories International Inc(CRL)の株式を保有している機関の数はいくつですか?

2025Q4時点で、Charles River Laboratories International Incの株式を保有している機関は1375社あり、保有株式の総市場価値は約52.90Mで、全体の107.49%を占めています。2025Q3と比較して、機関の持ち株は-22.06%増加しています。

Charles River Laboratories International Incの最大の収益源は何ですか?

FY2025Q3において、DSA部門がCharles River Laboratories International Incにとって最大の収益を生み出しており、その金額は600.68Mで、全収益の59.78%を占めています。
KeyAI